Former U.S. Army Surgeon General Ronald Blanck Joins Carrington Laboratories Board of Directors

IRVING, Texas, July 7, 2003—Carrington Laboratories, Inc. (Nasdaq: CARN) today announced that Dr. Ronald Ray Blanck, a retired lieutenant general and former Surgeon General of the U.S. Army and commanding general of the Army Medical Command, has been elected to the company’s board of directors. Dr. Blanck, 61, who is currently president of the UNT Health Science Center (UNTHSC) in Fort Worth, joins the existing six-member board. He assumed his current position at the UNTHSC shortly after retiring from the Army in July 2000.

During his 32-year military career, Dr. Blanck, a decorated Vietnam veteran, commanded Walter Reed Army Medical Center, the North Atlantic Regional Medical Command, overseas hospitals and medical centers and also held several senior medical positions. He received numerous Army awards, including the Bronze Star during his service in Vietnam from 1968-69, Legion of Merit, Meritorious Service Medal, Distinguished Service Medal, Defense Superior Service Medal, Joint Commendation Medal, Army Commendation Medal, Army Achievement Medal and Meritorious Unit Citation.

“Dr. Blanck brings unsurpassed expertise in military medicine, the way in which services are delivered and the myriad situations in which our products could benefit the treatment of military personnel and veterans,” said George DeMott, chairman of the board. “We expect him to be an important contributor as the board continually reviews and refines the marketing and production strategy for our advanced wound-care products and how they meet the military’s needs. Additionally, with his expertise as head of a large medical center, Dr. Blanck will aid us in developing new products.

“I also anticipate he will make a substantial contribution to our DelSite subsidiary’s development of a drug delivery platform for proteins and peptides and a means to deliver vaccines intranasally using sprays or powder,” DeMott added. “This is especially relevant in view of the President’s recent proposal of the nearly $6 billion ‘Project Bioshield’ program designed to accelerate the development and delivery of new vaccines to combat bioterrorism.
“During his army career, Dr. Blanck established himself as a foremost authority on preparation for mass casualties and in dealing with casualties resulting from biological and chemical agent exposure,” DeMott said. “He now chairs task forces on bioterrorism for both the Texas Medical Association and the American Osteopathic Association.”

Dr. Blanck added: “I look forward to working closely with a highly professional board and management team. I am especially impressed with ongoing research and development efforts, particularly the potential for DelSite’s technology to deliver drugs. This delivery system could revolutionize the vaccine industry.”

Dr. Blanck received his Bachelor of Science degree from Juniata College in Huntingdon, Pennsylvania, and graduated from the Philadelphia College of Osteopathic Medicine in 1967. He completed his internship at Lancaster (Pennsylvania) Osteopathic Hospital and his residency at Walter Reed Army Medical Center. He also attended the United States Army War College from 1985-86, where he was named class president.

He also has held numerous academic positions, including at Georgetown and Howard Universities in Washington, D.C., the Uniformed Services University School of Medicine, and the University of Texas Health Science Center at San Antonio.

About DelSite

DelSite Biotechnologies, Inc., a wholly owned subsidiary of Carrington, is an early stage biotechnology company established to commercialize its novel polymer drug delivery technology. Currently, DelSite is focusing its resources on developing delivery systems for vaccines, and therapeutic proteins and peptides that could benefit from improved injectable, intranasal and topical routes of administration. For more information, please visit and and click on “Subsidiaries.”

About Carrington

Carrington Laboratories, Inc., is an ISO 9001-certified, research-based biopharmaceutical company currently utilizing naturally occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care; manufacture and market the nutraceutical raw materials Manapol® and Hydrapol™; and market consumer products under the AloeCeuticals® brand. Carrington's technology is protected by more than 120 patents in 26 countries. Select products are honored with the internationally coveted CE mark, recognized by more than 20 countries around the world.

Carrington’s wholly owned subsidiary, Sabila Industrial, S.A., is the company’s bulk pharmaceutical manufacturing facility in Liberia, Costa Rica. The ISO 9000, USDA and FDA licensed manufacturing facility produces the company’s proprietary raw materials used in wound care, nutraceuticals and bulk materials for Acemannan Immunostimulant™ used in the treatment of fibrosarcoma in the veterinarian market. GelSite™, DelSite’s drug delivery platform for proteins and peptides, and GelVac™ materials for intranasal delivery of vaccines are also produced in this facility.

Certain statements in this release concerning Carrington may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the company's management; delays or problems in production; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission, including the Form 10Q filed May 14, 2003.

# # #

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.